282 related articles for article (PubMed ID: 17237677)
21. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
22. [The role of antiangiogenic agents in age related macular degeneration].
Tomi A
Oftalmologia; 2010; 54(4):63-72. PubMed ID: 21516865
[TBL] [Abstract][Full Text] [Related]
23. New treatments for age-related macular degeneration.
Imrie FR; Bailey C
Age Ageing; 2007 Jan; 36(1):8-10. PubMed ID: 17264135
[No Abstract] [Full Text] [Related]
24. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
25. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
26. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
27. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
28. [VEGF inhibitors in ophthalmology].
Thys J; Dupont G; Rakic JM
Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
[TBL] [Abstract][Full Text] [Related]
29. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Kaiser PK
Curr Med Res Opin; 2007 Mar; 23(3):477-87. PubMed ID: 17355729
[TBL] [Abstract][Full Text] [Related]
30. Expanding treatment options in age-related macular degeneration.
Bhisitkul RB; Rutar T
Int Ophthalmol Clin; 2006; 46(4):123-9. PubMed ID: 17060798
[No Abstract] [Full Text] [Related]
31. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Bressler SB
Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
[TBL] [Abstract][Full Text] [Related]
32. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
33. [Introduction to the topic: anti-VEGF therapy in the management of AMD].
Meyer CH
Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843
[No Abstract] [Full Text] [Related]
34. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient.
Rishi P; Sen PR; Shroff D; Chhablani J
Indian J Ophthalmol; 2008; 56(5):438-9. PubMed ID: 18711282
[No Abstract] [Full Text] [Related]
35. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E
Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
[TBL] [Abstract][Full Text] [Related]
36. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF therapy: riding the wave of change.
Hunyor AP
Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
[No Abstract] [Full Text] [Related]
38. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
39. [Age-related macular degeneration].
Parier V; Soubrane G
Rev Med Interne; 2008 Mar; 29(3):215-23. PubMed ID: 18262310
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of neovascular age-related macular degeneration with bevacizumab].
Monzón Moreno A
Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
